RECOMBINATE 500 IU

Land: Israel

Sprache: Englisch

Quelle: Ministry of Health

Wirkstoff:

COAGULATION FACTOR VIII RECOMBINANT 500 IU/VIAL

Verfügbar ab:

TEVA MEDICAL MARKETING LTD.

ATC-Code:

B02BD05

Darreichungsform:

POWDER FOR SOLUTION FOR INJECTION

Verabreichungsweg:

I.V

Hergestellt von:

BAXTER S.A., BELGIUM

Therapiegruppe:

COAGULATION FACTOR VII

Anwendungsgebiete:

The use of Recombinate is indicated in the treatment and prophylaxis of bleeding in patients with haemophilia A (congenital factor VIII deficiency). Recombinate is also indicated in the perioperative management of patients with haemophilia A. Recombinate is appropriate for use in children of all ages including the newborn. (Safety and efficacy studies have been performed in both previously treated and previously untreated children). The product in not suitable for the treatment of von Willebrand's disease.

Berechtigungsdatum:

2010-07-01